KIMBERLY KUREY: Open Payments
NPI 1326351032 · NEW LONDON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,801 in 96 payments from 14 companies in 2025. Trend: 2023 $2,503 · 2024 $1,630 · 2025 $1,801
Food & beverage: $1,801
| Company | Payments | Amount |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 25 | $389 |
| Axsome Therapeutics, Inc. | 13 | $378 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 24 | $303 |
| ABBVIE INC. | 11 | $248 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| Vanda Pharmaceuticals Inc. | 4 | $80 |
| Janssen Pharmaceuticals, Inc | 3 | $72 |
| Astellas Pharma US Inc | 3 | $70 |
| Tonix Medicines, Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 2 | $37 |
Products named: XTAMPZA, Auvelity, RELISTOR, REXULTI, VRAYLAR, FANAPT, SPRAVATO, Veozah.
Industry payments across CT — which companies pay providers there.
